Osteoporosis treatment
Jul 29, 2025
Ascendis Pharma’s SKYTROFA Approved by FDA for Adult Growth Hormone Deficiency; Apellis Wins FDA Approval for EMPAVELI in C3G and IC-MPGN Treatment; FDA Approves PTC Therapeutics’ Sephience for Phenylketonuria; MAIA Biotechnology’s Ateganosine Gets FDA Fast Track for Non-Small Cell Lung Cancer; Entera Bio Gets FDA Nod on BMD as Primary Endpoint for Phase III Osteoporosis Study
Ascendis Pharma’s SKYTROFA Approved by FDA for Adult Growth Hormone Deficiency Ascendis Pharma A/S announced that the FDA has approved SKYTROFA (lonapegsomatropin-tcgd) for the treatment of adult growth hormone deficiency (GHD). Already approved for pediatric GHD since 2021, SKYTROFA is a once-weekly prodrug of ...
Read More...
Dec 08, 2021
What All You Need to Know About Evolving Osteoporosis Therapeutic Landscape?
Osteoporosis can be characterized by a decrease in the density of bone, resulting in fragile bones which can decrease its strength. Osteoporosis leads to an extent of abnormally porous bones that are observed to be very compressible, just like a sponge. This skeleton disorder cripples the bones and consequently res...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
